

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) A method for inducing an immunological response against a malignant pancreatic cell in an individual, ~~said~~ wherein the method comprises ~~comprising the steps of:~~

(a) selecting an individual having malignant pancreatic cells or at risk for developing such a pancreatic tumor,

(b) administering to the individual a first poxvirus vector containing a ~~first gene, or antigenic portion thereof, that encodes~~ one or more DNA segments that encode (i) carcinoembryonic antigen (CEA) or an antigen portion thereof and (ii) mucin (MUC) or an antigen portion thereof or a modified version thereof, a pancreatic tumor-associated antigen (PTAA), and

(c) at regular intervals thereafter administering at least a second poxvirus vector containing a ~~gene encoding PTAA~~ one or more DNA segments that encode (i) carcinoembryonic antigen (CEA) or an antigen portion thereof and (ii) mucin (MUC) or an antigenic portion thereof thereof, wherein if CEA or MUC-1 or an antigenic portion thereof or a modified version thereof, thereof is the PTAA, there must be a second PTAA present.

such that an immunological response against the malignant pancreatic cell is induced in the individual.

2.-6. (Canceled)

7. (Currently Amended) The method according to claim 1, ~~7~~, wherein said poxvirus vector is selected from the group consisting of an orthopox virus vector; avipox virus vector; a suipox virus vector; a capripox virus vector; a leporipox virus vector; and an iridovirus vector.

8. (Currently Amended) The method according to claim 1, ~~6~~, wherein said poxvirus vector is a replication impaired or non-replicating poxvirus vector.

9. (Original) The method according to claim 8, wherein said poxvirus vector is an orthopox vector.

10. (Original) The method according to claim 9, wherein said orthopox virus vector is vaccinia.

11. (Canceled)

12. (Currently Amended) The method of claim 1, ~~11~~, wherein the PTAA ~~is a~~ mucin is selected from the group consisting of MUC-1, MUC-2, MUC-3, MUC-4, MUC-SAC, MUC-SB, MUC-6, MUC-7, MUC-11, MUC-12, and antigenic portions thereof and modified versions thereof.

13. (Currently Amended) The method of claim 12, ~~11~~, wherein the modified version thereof is wobbled-MUC.

14.-15 (Canceled)

16. (Currently Amended) The method of claim 13, ~~15~~, wherein the mucin is wobbled MUC-1 or wobbled mini-MUC.

17. (Currently Amended) The method of claim 1, ~~11~~, wherein the first vector is an orthopox vector, and the second vector is an avipox vector. ~~one to three administrations at set intervals are made by an orthopox vector containing the at least one PTAA or antigenic portion thereof and multiple administrations at set intervals are made by an avipox vector containing the at least one PTAA or antigenic portion thereof.~~

18. (Original) The method of claim 17, wherein the orthopox vector is vaccinia.

19. (Original) The method of claim 18, wherein the vaccinia is an attenuated vaccinia.

20. (Original) The method of claim 19, wherein the attenuated vaccinia is MVA or NYVAC.

21. (Currently Amended) The method of claim 17, wherein the orthopox vector is administered in one to three administrations at set intervals, and ~~before~~ the avipox vector is administered in multiple administrations at set intervals.

22. (Original) The method of claim 21, wherein the set interval is 20 days to 90 days.

23.-44. (Canceled)